Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain NKTR message board posts where the ticker symbol NKTR has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest NKTR SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-20-031018 Size: 5 KB
2020-05-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-20-031017 Size: 5 KB
2020-05-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-20-031016 Size: 6 KB
2020-05-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-20-031015 Size: 6 KB
2020-05-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-20-031014 Size: 7 KB
2020-05-20
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0000906709-20-000009 (34 Act)  Size: 5 MB
2020-05-08 000-24006
20858438
8-K  Documents   Interactive Data Current report, items 2.02 and 9.01
Acc-no: 0001213900-20-011292 (34 Act)  Size: 318 KB
2020-05-07 000-24006
20856756
DEFA14A  Documents Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Acc-no: 0001193125-20-126207 (34 Act)  Size: 87 KB
2020-04-29 000-24006
20830490
DEF 14A  Documents Other definitive proxy statements
Acc-no: 0001193125-20-126152 (34 Act)  Size: 1 MB
2020-04-29 000-24006
20830398
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-20-024928 Size: 11 KB
2020-04-17
More NKTR SEC Filings


Related news from
Sat, 06 Jun 2020
15:31:03 +0000
Why Is Nektar (NKTR) Up 12% Since Last Earnings Report?
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Thu, 04 Jun 2020
21:00:00 +0000
Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)
Nektar Therapeutics (NASDAQ:NKTR) today announced the presentation of results from the Phase 1b study evaluating multiple ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator, which is being developed as a potential therapeutic for a range of autoimmune disorders, including systemic lupus erythematosus (SLE).
Fri, 29 May 2020
21:00:00 +0000
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020)
Nektar Therapeutics (NASDAQ: NKTR) announced today that it will webcast an analyst and investor conference call on Friday, June 5, 2020 at 11:00 a.m. EDT during EULAR 2020. The event will follow Thursday's virtual poster presentation of the data from a Phase 1b multiple ascending dose study of NKTR-358, a first-in-class investigational regulatory T cell stimulator, in patients with systemic lupus erythematosus.
Tue, 26 May 2020
15:11:35 +0000
7 Stocks Maverick Capital Continues to Buy
Adobe and Avantor make the list Continue reading...
Fri, 22 May 2020
12:30:00 +0000
Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal
Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of Phase 1 clinical data for its lead immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) in combination with nivolumab, in Cancer Discovery, a journal of the American Association for Cancer Research. Previously published Phase 1 data in Cancer Discovery on BEMPEG, a CD122-preferential IL-2 pathway agonist, demonstrated that when administered as a monotherapy, it was well tolerated and showed clinical activity, including tumor shrinkage and durable disease stabilization, in heavily pretreated patients with solid tumor cancers.1 The manuscript published today presents the safety, immune-activation and efficacy results from a Phase 1 dose-escalation study conducted in 38 patients with immunotherapy-naïve, advanced solid tumors, including melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC).
Mon, 18 May 2020
12:05:07 +0000
Is There An Opportunity With Nektar Therapeutics's (NASDAQ:NKTR) 46% Undervaluation?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Nektar Therapeutics...
Sun, 17 May 2020
23:13:01 +0000
Oppenheimer Sticks to Their Hold Rating for Nektar Therapeutics
Oppenheimer analyst Jay Olson maintained a Hold rating on Nektar Therapeutics (NASDAQ:NKTR) on Sunday, setting a price target of $25, which is approximately 13.53% above the present share price of $22.02.
Tue, 12 May 2020
10:27:22 +0000
H.C. Wainwright Sticks to Their Hold Rating for Nektar Therapeutics
H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Hold rating on Nektar Therapeutics (NASDAQ:NKTR) on Tuesday, setting a price target of $26, which is approximately 25.18% above the present share price of $20.77.
Fri, 08 May 2020
14:29:02 +0000
Nektar's (NKTR) Q1 Earnings and Revenues Top Estimates
Nektar (NKTR) reports encouraging first-quarter 2020 results. The company continues to progress with its pipeline candidates.
Fri, 08 May 2020
08:12:41 +0000
Edited Transcript of NKTR earnings conference call or presentation 7-May-20 9:00pm GMT
Q1 2020 Nektar Therapeutics Earnings Call
Fri, 08 May 2020
07:31:06 +0000
Nektar Therapeutics (NKTR) Q1 2020 Earnings Call Transcript
NKTR earnings call for the period ending March 31, 2020.
Thu, 07 May 2020
21:55:09 +0000
Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of 34.57% and 12.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Thu, 07 May 2020
20:15:00 +0000
Nektar Therapeutics Reports First Quarter 2020 Financial Results
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2020.
Tue, 28 Apr 2020
21:00:00 +0000
Nektar to Announce Financial Results for the First Quarter 2020 on Thursday, May 7, 2020, After Close of U.S.-Based Financial Markets
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2020 on Thursday, May 7, 2020, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
Thu, 09 Apr 2020
22:08:01 +0000
Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays
In the span of eight days last month, CytomX Therapeutics Inc. landed a collaboration with Astellas Pharma and captured a $40 million milestone payment from AbbVie Inc. as it preps for a mid-stage cancer clinical trial. “It’s a challenging time for our industry,” said CytomX President and CEO Sean McCarthy.
Mon, 06 Apr 2020
10:24:06 +0000
Need To Know: Analysts Are Much More Bullish On Nektar Therapeutics (NASDAQ:NKTR) Revenues
Celebrations may be in order for Nektar Therapeutics (NASDAQ:NKTR) shareholders, with the analysts delivering a...
Mon, 30 Mar 2020
02:51:41 +0000
Hedge Funds Are Betting On Nektar Therapeutics (NKTR)
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
Thu, 12 Mar 2020
01:19:01 +0000
Edited Transcript of NKTR earnings conference call or presentation 27-Feb-20 10:00pm GMT
Q4 2019 Nektar Therapeutics Earnings Call
Sun, 01 Mar 2020
14:15:30 +0000
Nektar Therapeutics Just Reported And Analysts Have Been Cutting Their Estimates
It's been a sad week for Nektar Therapeutics (NASDAQ:NKTR), who've watched their investment drop 12% to US$20.81 in...
Fri, 28 Feb 2020
23:30:00 +0000
Nektar Therapeutics to Webcast Presentation at the Cowen and Company 40th Annual Health Care Conference
Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to present at the upcoming Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020 at 9:20 a.m. Eastern Time.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This is a site for sharing information about the atypical investments that the majority of investors have not discovered. It is about finding the next value/growth sector/investment before all the major houses on the Street are recommending it." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2020, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards